RESULTS
A statistically significant downregulation of FMN2 expression in large-scale human CRC expression datasets was found. Subsequent analysis showed that a high frequency of hypermethylation occurred in the FMN2 gene promoter in CRC tissues; operating characteristic curve analysis revealed that FMN2 gene methylation had a good capability for discriminating between CRC and nontumor tissue samples (AUC = 0.8432, P < 0.0001).
MethylTarget
™ assays showed that CRC cells and tissues displayed higher methylation of these CpG regions than nontumor tissue samples. Correlation analysis showed a strong inverse correlation between methylation and FMN2 expression, and the inhibition of DNA methylation with 5-Aza significantly increased endogenous FMN2 expression. Analysis of the association between FMN2 methylation patterns and clinical indicators showed that FMN2 methylation was significantly associated with age, N stage, lymphovascular invasion, and pathologic tumor stage. Notably, the highest methylation of FMN2 occurred in tissues from cases of early-stage CRC, including cases with no regional lymph node metastasis (N0), cases in stages Ⅰ and Ⅱ, and cases with no lymphovascular invasion, but the methylation level began to decrease with tumor progression. Additionally, FMN2 promoter hypermethylation was more common in patients > 60 years old and in colon cancer tissue.
INTRODUCTION
Colorectal cancer (CRC) is a common malignancy and a major cause of incidence and mortality in many coun tries, especially more developed countries [1] . Over the years, researchers have identified CRC as a gradual process that lasts for several years, since it begins as a single mutation in a cell until it becomes a detectable malignancy [2] . Therefore, the main secondary preventive strategy for CRC is the early detection of preneoplastic or neoplastic lesions in the large bowel [3] . Formin 2 (FMN2) is a member of the formin homo logy protein family; the encoded protein is thought to have essential roles in the organization of the actin cytoskeleton and in cell polarity [4] . More recently, FMN2 was reported to be involved in cancer, for example, ser ving as a potential oncogene in leukemia [5] . FMN2 can enhance the expression of the cell cycle inhibitor p21 by preventing its degradation. In addition, FMN2 is induced by the activation of other oncogenes, hypoxia, and DNA damage [6] . To date, only two studies have explored the relationship between FMN2 and CRC. The first study was in 2012; to identify the genetic determinants of colon tumorigenesis, Liu et al [7] and colleagues carried out a genomewide association study of azoxymethane induced colon tumorigenesis and subsequently confirmed through fine mapping that FMN2 is associated with co lon tumor susceptibility. Another study [8] assessed the expression of FMN2 in tumor and adjacent nontumor tissue by immunohistochemistry, with results showing that FMN2 was predominantly localized in the cytoplasm of tumor cells; that the rate of positive FMN2 protein expression in the CRC and paracarcinoma tissues was 53.73% (180/335) and 80.90% (271/335), respectively, with a significant difference (P < 0.05); and that the level of the FMN2 protein in CRC patients was associated with tumor differentiation, TNM stage, and lymph node metastasis. However, the mechanism leading to the downregulation of FMN2 expression in CRC has not been studied. In this article, we tried to show that the high frequency of hypermethylation occurring in the pro moter of the FMN2 gene in CRC tissues is responsible for the silencing of FMN2, and we further explored the association between FMN2 methylation and clinical in dicators. We found that the highest level of FMN2 methy lation occurred in earlystage CRC tissues; thus, FMN2 may provide a new biomarker for the secondary pre vention of CRC.
MATERIALS AND METHODS

Cell lines and tissue samples
Human CRC cell lines (SW620 and SW480) were cul tured in L15 medium (KeyGEN BioTECH, Nanjing, China) supplemented with 10% fetal bovine serum (FBS) (Bio logical Industries, Israel), and HCT116 and HT29 cells were cultured in McCoy's 5A medium (KeyGEN BioTECH, Nanjing, China) supplemented with 10% FBS. Cells were grown in a 5% CO2 cell culture incubator at 37 ℃.
Clinical samples were obtained from patients treated at the Third Xiangya Hospital of Central South University (Hunan, China) under informed consent and approval by the Ethics Committee of Central South University (more details about the clinical samples can be found in Table 1 ).
RNA purification and reverse transcription-PCR
Total RNA was extracted using TRIzol reagent (Invitrogen, United States). The reverse transcription reaction was performed using ReverTra Ace qPCR RT Master Mix with gDNA Remover (TOYOBO, Japan), and this kit includes reagents for reverse transcription and for the removal of genomic DNA (DNase Ⅰ treatment). cDNA was amplified with KOD SYBR ® qPCR mix (TOYOBO, Japan) on a LightCycler ® 480Ⅱ system (Roche) according to the manufacturer's instructions (FMN2 primers: forward, GCGAACGCTGTTGGAGAAG and reverse, CTGATTACACGGTTCCCTGAAG).
Treatment with 5-aza-2'-deoxycytidine
Cells were grown in appropriate culture conditions. For demethylation treatment, colorectal cells were treated with 5aza2'deoxycytidine (5Aza) (Sigma, United States) for 96 h (5 μmol/L), with daily replacement of the drug and medium. Untreated cells were used as a control group.
DNA extraction and bisulfate treatment
DNA was isolated with an Easypure Genomic DNA kit (TransGen Biotech, Beijing, China) according to the manufacturer's instructions. The DNA concentration was assessed by spectrophotometry and confirmed by gel electrophoresis; DNA was stored at 20 ℃. An EZ DNA Methylation Gold ™ Kit (Zymo Research Corporation, CA, United States) was used to convert all unmethylated cytosine to uracils.
DNA methylation analysis
MethylTarget
™ assays (targeted bisulfite sequencing) developed by Genesky BioTech (Shanghai, China) were carried out as previously described [9, 10] . Briefly, CpG islands adjacent to the promoter region of the FMN2 gene were analyzed, and based on these CpG islands, four CpG regions from CpG islands in FMN2 were se quenced (the details, including the relative distance from the transcriptional start site, amplification primers, and product size, of these CpG regions can be found in Tables  2 and 3 ). Genomic DNA was converted with bisulfite, and PCR was performed to amplify the targeted DNA sequences. The products were sequenced on an Illumina MiSeq benchtop sequencer (Illumina, CA, United States).
Bioinformatics
Cosmic [11] , a database cataloguing somatic mutations in human cancer, was used to assess methylation mu tations in human cancer tissues. Datasets for CRC, in cluding GEO GSE20842, GSE8671, and GSE4183, as well as TCGA [12] , were used to assess the expression level Start: The starting position of the product on the reference genome; TSS: The mRNA transcription initiation site; End: The end position of the product on the reference genome; Length: the product length; Target strand: The product orientation; Distance2TSS: The distance from the product to the TSS. Figure 1E ). We next assessed the accuracy of the FMN2 methylation signature for the detection of CRC via receiver operating characteristic curve analysis, and the analysis revealed a good capability for discriminating between CRC and nonneoplastic tissue specimens (AUC = 0.8432, 95%CI: 0.80220.8841; P < 0.0001) ( Figure 1F ).
Primer name Primer
FMN2_1_F GAGGGTYGGGATGGTTTGAG FMN2_1_R CCCCCRCTCCCCTTCTTT FMN2_2F GAGTGTGYGGATTTTTTTGAGGT FMN2_2R AAATATCTAAAAACAAATCCTCTTACTCC FMN2_3F GATTTGTTYGAGAGTTTGGTTGT FMN2_3R AAACRCATCCTCAAAAACATCCT FMN2_4F TTTTTGAGTYGAGGGTTTAGAATTG FMN2_4R CACRTTCTAAAAACCATCCRCAAC
Analysis of the features of methylation-associated FMN2 silencing in CRC tissue and cells
The majority of research indicates that promoter hyper methylation is a key mediator underlying the down regulation of gene expression. The high frequency of hypermethylation in the FMN2 gene promoter and the significant inverse correlation between methylation levels and the expression of FMN2 in 372 CRC tissues ( Figure 2A ) remind us that methylation is the main cause of FMN2 gene silencing. To investigate this topic, nine paired colorectal tumor samples and adjacent nontumor tissue samples (for details, see Table 1 ) were selected for RTqPCR and MethylTarget ™ assays. We first examined FMN2 expression using RTqPCR in these paired samples. A significant reduction in FMN2 expression was observed in seven of the nine CRC tissues ( Figure 2B ). Then, based on the CpG islands adjacent to the FMN2 promoter region, four CpG regions (FMN21, FMN22, FMN23, and FMN24, the details of which can be found in Table  2 ) from CpG islands were amplified and sequenced. The result demonstrated that CRC tissues revealed a stronger methylation pattern than noncancerous tissues and identified three CpG regions, namely, FMN22, FMN23, and FMN2-4, with a statistically significant difference (P = 0.0069, P = 0.0094, and P = 0.0005, respectively) ( Figure 2CF ; Table 2 ). Notably, tumor tissues (cases 1, 37, and 9) exhibiting lower FMN2 expression than the corresponding noncancerous tissues displayed an increase in methylation at these islands compared with the noncancerous tissues, whereas CRC cases 2 and 8, with moderate FMN2 expression, revealed a methylation pattern similar to that of the corresponding noncancerous tissues. Correlation analysis revealed a strong inverse correlation between the methylation of island 2 (r = 0.86), island 4 (r = 0.71), and island 3 (r = 0.78) of FMN2. Data about DNA methylation, the patients, and the samples were downloaded from the TCGA database (https://cancergenome.nih.gov/).
Statistical analysis
GraphPad Prism 7 software was used to analyze the data. The methylation and expression levels in normal, adenoma, and cancerous tissues, as well as the me thylation level in different clinical materials, were as sessed by twotailed unpaired Student's ttests; box whisker plots depict the means, 1 st and 3 rd quartiles, and minimum/maximum. The error bars in the figures represent SDs. Spearman's correlation coefficient (r) was used to determine the correlation. Overall survival (OS) and diseasefree survival (DFS) were estimated using the KaplanMeier method. Receiver operating characteristic curves were constructed based on the level of FMN2 methylation. The data were considered nonsignificant for P > 0.05.
RESULTS
Analysis of FMN2 expression in large-scale human CRC expression datasets
Previous studies demonstrated that FMN2 is underex pressed in CRC. To further confirm the expression characteristics of FMN2 in CRC, we expanded our analysis to published, largescale human CRC expression datasets. GSE20842, which contains 65 paired samples of tumor and mucosal tissue samples from 65 CRC patients, was used to assess FMN2 expression; we found a statistically significant downregulation of FMN2 expression from normal colorectal tissue to carcinoma tissue (P < 0.0001) ( Figure 1A ). An identical pattern was observed in human CRC samples from TCGA (P < 0.0001); however, it is noteworthy that we found that the expression level of FMN2 was significantly lower in early-stage CRC tissues (stages Ⅰ + Ⅱ vs stages Ⅲ + Ⅳ, P = 0.02) ( Figure 1B ), which indicates that FMN2 downregulation may be an important early event in CRC. To confirm this finding, GSE8671, which contains 32 colorectal adenoma and corresponding normal colonic mucosa samples, was downloaded to analyze FMN2 expression; we found a sta tistically significant downregulation of FMN2 expression from normal colorectal tissue to adenoma tissue (P < 0.0001) ( Figure 1C ). In addition, we downloaded the GSE4183 dataset, which contains colonic biopsies of 15 patients with CRC, 15 patients with adenoma, and 8 healthy normal controls, to simultaneously assess the reduction of FMN2 in adenomas and cancer tissues. As shown in Figure 1D , adenoma tissues displayed a greater reduction in expression (P = 0.0002) than tumor tissues (P = 0.01).
High frequency of hypermethylation occurs in the FMN2 gene promoter in CRC tissues
Somatic mutation in cancer is an important reason for the aberrant expression of genes, so the Catalogue of Somatic Mutations in Cancer (COSMIC), the world's and FMN2 expression (data not shown). In addition, we assessed the methylation level of each CG site in CpG island regions and found that 8 of 14 CG sites in FMN21 and all CG sites in FMN22 (13/13), FMN23 (23/23), and FMN24 (27/27) revealed a significantly stronger methylation pattern in the tumor tissues than in the corresponding noncancerous tissues (Table 4) . We next wondered whether promoter hypermethy lation at these loci and FMN2 expression are causally related. To answer this question, four CRC cell lines (HCT116, HT29, SW480, and SW620) were selected for MethylTarget ™ assays. The result revealed a high level of DNA methylation in all CRC cell lines, whereas only limited methylation was observed in normal colon tissue from a healthy individual ( Figure 3A) . Then, we treated HCT116, HT29, and SW480 cells with 5Aza; Table 2) . the inhibition of DNA methylation by 5-Aza significantly increased the endogenous FMN2 expression ( Figure 3B ).
FMN2 promoter hypermethylation is an early event in CRC
To analyze the clinicopathological significance of FMN2 promoter methylation, we divided the patients into a highmethylation group and a lowmethylation group according to the median value of methylation. The as sociation between clinicopathological factors and FMN2 methylation was analyzed (Table 5 ). High FMN2 methy lation was associated with age (P = 0.0006), N stage (P = 0.0293), pathologic tumor stage (P = 0.0161), and lymphovascular invasion (P = 0.0180). Notably, the association analysis showed that the highest methylation level of FMN2 occurred in tissues from cases of early stage CRC, including cases with no regional lymph node metastasis (N0), cases in stages Ⅰ and Ⅱ, and cases with no lymphovascular invasion; the methylation level began to decrease with tumor progression. To understand our conclusions more intuitively, we then performed unpaired ttests based on the pathological data. An identical pat tern is shown in Figure 4AC ; DNA methylation of the FMN2 gene increased from normal tissues to cancer tissues, reaching the highest level in earlystage cancer (N0, stages Ⅰ and Ⅱ, and no lymphovascular invasion) and decreasing stepwise in advancedstage carcinomas. However, it is worth noting that the methylation level of FMN2 in advanced-stage carcinomas is still significantly higher than that in normal tissue (P < 0.0001). Addi tionally, we analyzed the methylation level of FMN2 ac cording to the primary tumor site, and the result showed that there were statistically significant differences among the means (P < 0.0001) and that tumors located in the sigmoid colon and rectum had a relatively low FMN2 me thylation level ( Figure 4D ). Furthermore, we found that FMN2 promoter hypermethylation was not associated with OS or DFS ( Figure 4E and F). All these results indicated that FMN2 promoter hypermethylation mainly occurred in elderly and earlystage patients with colon cancer.
DISCUSSION
In this article we first reported that a high frequency of hypermethylation occurred in the promoter of the FMN2 gene in CRC tissues and that hypermethylation was responsible for the silencing of FMN2, which suggests that the epigenetic silencing of FMN2 may be an im portant event in CRC. To the best of our knowledge, although FMN2 was one of the top 20 genes with an extremely high frequency of hypermethylation in CRC (COSMIC, https://cancer.sanger.ac.uk/cosmic), this study is the first and only to investigate the regulation of the FMN2 gene by methylation. Previously, studies and investigations of publicly available datasets in FireBrowse (http://firebrowse.org/) have demonstrated differential FMN2 RNA expression in human tumors, depending on the tumor type. For example, FMN2 is overexpressed in approximately 95% of preB acute lymphoblastic leukemias [5] but is underexpressed in kidney renal clear cell carcinoma (FireBrowse); the mechanism underlying these pheno mena has not been studied. In our research, we iden tified that FMN2 is underexpressed in CRC tissues and were the first to explore the underlying mechanism. Epigenetic modifications of DNA, such as DNA promoter hypermethylation, have critical roles in mediating gene expression in mammalian development and human disease [13] . Methylationmediated silencing of some genes in CRC has been reported in previous studies; for example, Lgr5 methylation, by effecting Lgr5 expression and CRC stem cell differentiation, may serve as a novel prognostic marker in CRC patients [14] . SMYD3 promoter hypomethylation suppressed SMYD3 expression and was associated with the risk of CRC [15] . Based on the fact that a high frequency of hypermethylation occurred in the FMN2 gene promoter in CRC tissues, we found that both the downregulation of FMN2 expression and the high frequency of hypermethylation occurred at the earliest stages of carcinogenesis; furthermore, these parameters had a significant inverse correlation in both our study and in published, largescale human CRC electronic datasets. We also carried out MethylTarget ™ assays in paired CRC tissues and inhibited DNA methylation with 5Aza in CRC cells, which identified that hypermethylation and FMN2 expression are causally related. It is particularly important to determine which CpG islands adjacent to the promoter affect the expression of a gene, because this knowledge can provide direc tions for future research and potential targets for treatment. For example, Tavazoie SF [16] found that the Mest/miR-335 promoter contained three CpG islands upstream of the transcriptional start site; among these CpG islands, island 3 demonstrated a strong inverse correlation between methylation and miR335 expression connected; E and F: FMN2 hypermethylation has no effect on the overall survival or disease-free survival of CRC patients.
(r 2 = 0.81). The methylation status of island 3 plays a key role in inhibiting miR335 expression. An identical pattern was observed in our study; we found that al though the methylation status of FMN22, 3 and 4 was significantly increased in the eight CRC tissues, the methylation of FMN2-1 was not significantly higher than that in the paired nontumor tissues. All these findings suggest that during CRC progression, FMN2 expression may be mainly mediated by the methylation of a specific CpG island region in the FMN2 promoter.
In addition, we found that the hypermethylation of FMN2 was significantly associated with age, N stage, pathologic tumor stage, and lymphovascular invasion. Notably, the association analysis showed that the highest methylation level of FMN2 occurred in tissues from cases of earlystage CRC, including cases with no regional lymph node metastasis (N0), cases in stages Ⅰ and Ⅱ, and cases with no lymphovascular invasion and that the methylation level began to decrease with tu mor progression. Identical results have been reported in previous research. In endometrial tumorigenesis, SchneiderStock [17] found that DNA methylation of the APC gene increased from atypical hyperplasia (23.5%) to endometrial carcinoma, reaching its highest level of 77.4% in earlystage cancer (FIGO stages Ⅰ and Ⅱ) and decreasing stepwise to 24.2% in advanced stage carcinomas (FIGO stages Ⅲ and Ⅳ). Epigenetic inactivation of the candidate tumor suppressor USP44 is a frequent and early event in colorectal neoplasia [18] , and P16 methylation is an early event in cervical car cinogenesis [19] . All these studies, along with ours, have identified that DNA hypermethylation can be an early event in tumorigenesis. Hypermethylation most likely plays a critical role in cancer initiation, and creates an environment conducive to the overwhelming accumu lation of simultaneous genetic and epigenetic muta tions [20] . Additionally, we identified that patients younger than 60 years and patients with tumors located in the sigmoid colon and rectum exhibit relatively low FMN2 methylation levels, which indicates that the methylation associated silencing of FMN2 may be involved in specific patients. In addition, Grady [21] identified that the patterns of DNA methylation in the colon vary by anatomical location, patient gender, and patient age. In summary, we identified that the RNA expression of FMN2 is reduced in CRC tissues and were the first to reveal that the hypermethylation of specific CpG islands adjacent to the FMN2 promoter is the mecha nism underlying FMN2 silencing. Although the FMN2 methylation is significantly stronger in tumor tissues than in paired nontumor tissues, the methylation level begins to decrease with tumor progression, which suggests that DNA hypermethylation is an early event in CRC tumo rigenesis and can serve as a biomarker for the detection of CRC.
ARTICLE HIGHLIGHTS
Research background
Colorectal cancer (CRC) is a critical contributor to cancer mortality and morbidity, and some critical genes and pathways were important in the initiation and progression of CRC. Recent studies have shown that formin 2 (FMN2) may be down-regulated in CRC. Whether FMN2 is abnormally expressed in CRC and what causes its abnormal expression are unclear. Revealing the role of FMN2 in CRC may provide potential therapeutic targets.
Research motivation
Epigenetic modifications of DNA, especially promoter hypermethylation, have critical roles in mediating some gene expression in the initiation and progression of CRC. Whether abnormal DNA methylation changes can occur in the promoter of the FMN2 gene in CRC and whether such changes can be responsible for the silencing of FMN2 are poorly known. So the main topic in this article is to try to solve this question that epigenetic silencing of FMN2 may be an important event in CRC. All can provide the basis and direction for future research.
Research objectives
This study focuses on whether FMN2 is underexpressed in CRC, and whether methylation changes occur in CpG islands located in the promoter region of 
Research methods
Large-scale human CRC expression datasets, including GEO and TCGA, were used to assess the expression levels and methylation levels of FMN2 in CRC. Then, the mRNA levels of FMN2 in our own clinical samples was analyzed by real-time quantitative polymerase chain reaction, and the methylation levels in four CpG regions adjacent to the FMN2 promoter were assessed by MethylTarget ™ assays in CRC cells and in paired colorectal tumor samples and adjacent nontumor tissue samples. Furthermore, we performed demethylation treatment in CRC cells with 5-Aza-2'-deoxycytidine and assessed the expression of FMN2 by qRT-PCR. Last, the association between FMN2 methylation patterns and clinical indicators was analyzed.
Research results
FMN2 is underexpressed in CRC, and the most obvious low expression occurs in early colon cancer tissues. Subsequent analysis coming from largescale human CRC datasets showed that FMN2 was one of the top 20 genes with an extremely high frequency of hypermethylation in CRC, methylation was the main somatic mutation, and FMN2 gene promoter hypermethylation occurred in 37.37% of CRC tissues. Our own experiments confirmed that CRC cells and tissues displayed higher methylation levels in CpG regions of FMN2 than nontumor tissue samples. Correlation analysis showed a strong inverse correlation between methylation and FMN2 expression. Treatment of CRC cells with demethylation reagent, 5-Aza-2'-deoxycytidine, can significantly increase endogenous FMN2 expression. The highest methylation of FMN2 occurred in tissues from cases of early-stage CRC, including cases with no regional lymph node metastasis (N0), cases in stages I and II, and cases with no lymphovascular invasion. Additionally, FMN2 promoter hypermethylation was more common in patients > 60 years and in colon cancer tissue.
Research conclusions
In this article we confirmed the low expression of FMN2 in CRC and first reported that a high frequency of hypermethylation occurred in the promoter of the FMN2 gene in CRC tissues and that hypermethylation was responsible for the silencing of FMN2. It is worth noting that we found that the low expression and hypermethylation of FMN2 occurred more prominently in early colon cancer tissues, which suggests that DNA hypermethylation leading to the low expression of the FMN2 gene may be an important early event in CRC, most likely playing a critical role in cancer initiation, and can serve as an ideal diagnostic biomarker in elderly patients with early-stage colon cancer.
Research perspectives
In the era of big data, the rational use of tumor databases such as TCGA, GEO, and COSMIC can provide us with valuable information. The emergence of some new technologies can provide more accurate data for our experiments.
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